Case Type: Mergers & Acquisitions

Prometheus Biosciences, Inc. (NASDAQ: RXDX), relating to its proposed sale to Merck and Co. Under the terms of the agreement, RXDX shareholders are expected to receive $200.00 in cash per share they own.

Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA), relating to its proposed sale to Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the agreement, STSA Shareholders are expected to receive one non-tradeable CVR of up to $5.77 in cash plus $0.91 in cash per share they own.

Charah Solutions, Inc. (OTC: CHRA), relating to its proposed sale to SER Capital Partners/ Under the terms of the agreement, CHRA shareholders are expected to receive $6.00 in cash per share they own.

Camber Energy, Inc. (NYSE: CEI), relating to its proposed merger with Viking Energy Group, Inc.

TESSCO Technologies Inc. (NASDAQ: TESS), relating to its proposed sale to affiliates of Lee Equity Partners and Twin Point Capital. Under the terms of the agreement, TESS shareholders are expected to receive $9.00 in cash per share they own.

Diversified Healthcare Trust (NASDAQ: DHC), relating to its proposed merger with Office Properties Income Trust. Under the terms of the agreement, DHC shareholders are expected to receive 0.147 shares of Office Properties per share they own.

National Instruments Corp. (NASDAQ: NATI), relating to its proposed sale to Emerson Electric Co. Under the terms of the agreement, NATI shareholders are expected to receive $60.00 in cash per share they own.

Life Storage, Inc. (NYSE: LSI), relating to its proposed merger with Extra Space Storage Inc. Under the terms of the agreement, LSI shareholders are expected to receive 0.8950 shares of Extra Space per share they own.

Heska Corp. (NASDAQ: HSKA), relating to its proposed sale to Mars, Inc. Under the terms of the agreement, HSKA shareholders are expected to receive $120.00 in cash per share they own.

Diffusion Pharmaceuticals, Inc. (NASDAQ: DFFN), relating to its proposed merger with EIP Pharma Inc